Novo Nordisk shares drop 6% as US GLP-1 outlook disappoints
Second-quarter sales reached 78.49 billion kroner, but the newly launched Wegovy pill missed analyst expectations at 3.22 billion kroner.
The wire
- 01Novo raised 2026 adjusted sales guidance to down 6% to flat at constant currency, yet US-traded shares fell about 6% on the outlook for declining US sales.
- 02The company cited GLP-1 prescription trends, intensifying competition, reduced Medicaid obesity coverage and lower realized US prices under its most-favored-nation deal with President Trump.
- 03Oral Wegovy has passed 5 million prescriptions since its January launch, CEO Mike Doustdar said; full earnings were due the following day alongside Eli Lilly's.
From the source
Read at cnbc.comNovo Nordisk shares slide after guidance disappoints investors
U.S.-traded shares of Novo Nordisk dropped about 6% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors.